Exforge Hct Tablet, Film Coated
Product Images NDC 0078-0563

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Exforge Hct (NDC 0078-0563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Amlodipine Structural Formula (Exforge Hct 01)

Amlodipine Structural Formula (Exforge Hct 01)
FDA Label Image

Valsartan Structural Formula (Exforge Hct 02)

Valsartan Structural Formula (Exforge Hct 02)
FDA Label Image

Hydrochlorothiazide Structural Formula (Exforge Hct 03)

Hydrochlorothiazide Structural Formula (Exforge Hct 03)
FDA Label Image

Figure 1: Reduction In Mean Blood Pressure At Endpoint (Exforge Hct 04)

Figure 1: Reduction In Mean Blood Pressure At Endpoint (Exforge Hct 04)
FDA Label Image

Figure 2: Mean Sitting Diastolic Blood Pressure By Treatment And Week (Exforge Hct 05)

Figure 2: Mean Sitting Diastolic Blood Pressure By Treatment And Week (Exforge Hct 05)
The text provides a chart displaying Mean Sitting Diastolic Blood Pressure (DBP) in mmHg, with various treatment options including AMNAHCTZ, ValHCTZ, and HCTZAMI, along with their respective dosages.*
FDA Label Image

Figure 3: Mean Sitting Systolic Blood Pressure By Treatment And Week (Exforge Hct 06)

Figure 3: Mean Sitting Systolic Blood Pressure By Treatment And Week (Exforge Hct 06)
FDA Label Image

Figure 4: Mean Ambulatory Diastolic Blood Pressure At Endpoint By Treatment And Hour (Exforge Hct 07)

Figure 4: Mean Ambulatory Diastolic Blood Pressure At Endpoint By Treatment And Hour (Exforge Hct 07)
FDA Label Image

Figure 5: Mean Ambulatory Systolic Blood Pressure At Endpoint By Treatment And Hour (Exforge Hct 08)

Figure 5: Mean Ambulatory Systolic Blood Pressure At Endpoint By Treatment And Hour (Exforge Hct 08)
FDA Label Image

Principal Display Panelpackage Label – 5 mg / 160 mg / 12.5 mgrx Only Ndc 0078-0559-15exforge Hct® (amlodipine, Valsartan, Hydrochlorothiazide)5 mg* / 160 mg / 12.5 mg*each Tablet Contains 6.9 mg Of Amlodipine Besylate30 Tablets (Exforge Hct 09)

Principal Display Panelpackage Label – 5 mg / 160 mg / 12.5 mgrx Only Ndc 0078-0559-15exforge Hct® (amlodipine, Valsartan, Hydrochlorothiazide)5 mg* / 160 mg / 12.5 mg*each Tablet Contains 6.9 mg Of Amlodipine Besylate30 Tablets (Exforge Hct 09)
FDA Label Image

Exforge Hct 10

Exforge Hct 10
FDA Label Image

Exforge Hct 11

Exforge Hct 11
FDA Label Image

Exforge Hct 12

Exforge Hct 12
This appears to be a description of a medication prescribed for high blood pressure, consisting of a combination of amlodipine, valsartan, and hydrochlorothiazide. The medication is produced by Novartis and is available in pack size of 30 tablets. The dosage of amlodipine is 10mg, valsartan is 160mg, and hydrochlorothiazide is 25mg per tablet. The text also includes a product code, NOC 078.05 and a GTIN code, 0030078052157.*
FDA Label Image

Exforge Hct 13

Exforge Hct 13
This is a description of a medication called Twynsta HCT. It's a combination of amlodipine, valsartan, and hydrochlorothiazide tablets used to treat hypertension. The tablets are taken orally and come in a bottle containing 30 tablets. The dosage strength is 10mg of amlodipine, 320mg of valsartan, and 25mg of hydrochlorothiazide. The manufacturer is Novartis.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.